Deferred Tax Assets, Operating Loss Carryforwards of Regencell Bioscience Holdings Ltd from 30 Jun 2019 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Regencell Bioscience Holdings Ltd quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 30 Jun 2019 to 30 Jun 2025.
  • Regencell Bioscience Holdings Ltd Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 30 Jun 2025 was $3,338,878, a 20% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

Regencell Bioscience Holdings Ltd Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $3,338,878 +$551,002 +20% 30 Jun 2025 20-F 31 Oct 2025 2025 FY
Q2 2024 $2,787,876 +$482,109 +21% 30 Jun 2024 20-F 31 Oct 2025 2025 FY
Q2 2023 $2,305,767 +$848,051 +58% 30 Jun 2023 20-F 31 Oct 2025 2025 FY
Q2 2022 $1,457,716 +$798,047 +121% 30 Jun 2022 20-F 25 Oct 2024 2024 FY
Q2 2021 $659,669 +$222,213 +51% 30 Jun 2021 20-F 27 Oct 2023 2023 FY
Q2 2020 $437,456 +$134,041 +44% 30 Jun 2020 20-F 31 Oct 2022 2022 FY
Q2 2019 $303,415 30 Jun 2019 20-F 29 Oct 2021 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.